SOM Biotech’s Post

As we head into #JPM, we’re pleased to announce the launch of the new SOM Biotech website. The updated site reflects who we are today: a late-stage clinical development company with a Phase 3–ready asset, pioneering AI-driven drug discovery, and a continued focus on developing treatments for rare and underserved CNS disorders. Ahead of a busy week of conversations in San Francisco, the new site provides a clearer view of our products, science, and commitment to patients and families. We invite you to explore the new website and connect with us during JPM.

  • No alternative text description for this image

nice Aieleen - we need new game changers in CNS- keep doing well

Like
Reply

To view or add a comment, sign in

Explore content categories